National Institute of Advanced Industrial Science and Technology

National Center for Global Health and Medicine

Tokyo Medical University

Sysmex Corporation

Nagoya University

Wako Pure Chemical Industries, Inc.

University of Tsukuba

The University of Toyama

Public University Corporation Nagoya City University

Science & Technology Corporation

Glycobiomarker Leading Innovation Co., Ltd.

National Institute of Advanced Industrial

Nagoya City University

Atsushi Kuno

Hisashi Narimatsu

Yuzuru Ikehara

Jun Hirabayashi

Akira Togayachi

Hiroyuki Kaji

Maki Sogabe

Masashi Mizokami

Hideki Matsuzaki

Takashi Ohkura

Masayuki Noguchi

Masaharu Nomura

Yasuhito Tanaka

Yoshitoshi Hirao

Hiromi Ito

Jun Iwaki

Noboru Uchiyama

Minako Abe

Yasuhiro Hashimoto

Keiro Shirotani

Masakazu Fukuda

Takashi Sato

Yasunori Chiba

Makoto Asashima

Hiroaki Tateno

Shinya Nagai

Youichi Takahama

Chikayuki Tsuruno

Yasuko Onuma

Yuzuru Ito

Masaki Warashina

Yoshinobu Kariya

Kiyoaki Ito

Kyoka Hoshi

Shunsuke Matsubara

Takashi Kagawa

Satoshi Futakawa

Junichi Shoda

Atsushi Matsuda

Hajime Arai

Toru Kawamoto

Masakazu Miyajima

Sachiko Nakamura

Kazuo Fujihara

Kiyohiko Angata

Hiroki Shimizu

Takanori Wagatsuma

Masaaki Korenaga

Kazuto Tajiri

Tatsuhiko Ozawa

Takashi Angata

Toshihide Shikanai

Kiyomitsu Nara

Makoto Ochou

An examination system that recognizes a glycosylated antigen in Dane particles of hepatitis B virus (HBV) and a neutralizing antibody that recognizes the glycosylated antigen and that exhibits an infection-inhibiting activity. It was elucidated that Dane particles are associated with specific glycan structures, and this enabled the construction of a new detection system for infectious, i.e., nucleic acid-containing, hepatitis B virus particles and the provision of a neutralizing antibody that recognizes a glycosylated antigen and that exhibits an infection-inhibiting activity.

Method for efficiently inducing antibody, antibody and detection system for hepatitis virus

An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.

Lung cancer differential marker

It is intended to develop and provide a method for detecting a particular glycan-isoform rapidly and specifically by a small number of steps. The present invention provides a glycan-isoform detection method comprising quantifying an immune complex formed by the mixing of a test sample with a sugar chain non-reducing terminal residue-binding lectin and an antibody specifically binding to the protein moiety of the glycan-isoform, etc., comparing the obtained amount of the immune complex with the amount of a control immune complex obtained when a control sample is not mixed with the sugar chain non-reducing terminal residue-binding lectin or is mixed with a control protein, and determining the presence or absence of the glycan-isoform of interest in the test sample on the basis of the difference between these amounts.

Glycoform detection method and glycoform detection device

The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.

Method for enrichment and separation of spinal fluid glycoprotein, method for searching for marker for central nervous system diseases which utilizes the aforementioned method, and marker for central nervous system diseases

The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.

Glycan markers as measure of disease state of hepatic diseases

An object of the present invention is to provide a method for evaluating a differentiation status of cells using a culture supernatant of stem cells. Provided is 'undifferentiation sugar chain marker' composed of the sugar chain structure 'Fuc&#x3b1;1-2Gal&#x3b2;1-3GlcNAc' or &#x201c;Fuc&#x3b1;1-2Gal&#x3b2;1-3GalNAc&#x201d; and capable of sensitively determining the undifferentiated state of stem cells using a culture supernatant of stem cells. Also found is BC2LCN lectin or a modified product thereof capable of sensitively recognizing the &#x201c;undifferentiation sugar chain marker&#x201d; as excellent &#x201c;probe for detecting the undifferentiation sugar chain marker&#x201d; capable of determining the undifferentiation status of cells using a culture supernatant.

Undifferentiated cell detection method and complex carbohydrate detection method

An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Disclosed is a method for measuring at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject, comprising: measuring AGP binding to a first lectin selected from AOL and MAL, when the glycoprotein is AGP; and measuring M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII, when the glycoprotein is M2BP.

Method for measuring glycoprotein, method for examining liver disease, reagent for quantitative determination of glycoprotein, and glycan-marker glycoprotein as an index for clinical conditions of liver disease

An analyzer of the present invention for analyzing a glycan or a complex glycan includes a substrate, a fluorescent labeling excitation means and a fluorescent intensity measurement means. The substrate comprises a rectangle photoconductive base plate coated by a compound containing an active group to fix protein by an amino group thereof, one and more open-topped reaction vessel formed on a surface of the base plate, and plural spots of glycan binding proteins arranged in a matrix and immobilized on the surface of the base plate in the reaction vessel. The fluorescent labeling excitation means which excites fluorescent label by generating evanescent-waves on the surface of the substrate comprises a pair of optical fibers arranged toward the both side end faces of the right and left of the substrate to introduce a light thereinto.

Analyzer for glycan or complex carbohydrate

Disclosed are a method for early, sensitively and reliably detecting and distinguishing intrahepatic cholangiocarcinoma in a malignant tumor occurring primarily in the liver in a simple way, and a kit thereof. In the method, a glycan biomarker consisting of a lectin WFA (Wisteria floribunda Agglutinin)-binding glycoprotein derived from intrahepatic cholangiocarcinoma is used as a cancer marker to detect intrahepatic cholangiocarcinoma by detecting the cancer marker in a test specimen. The method for detecting intrahepatic cholangiocarcinoma can clearly differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma and enables early detection and determination with a performance clinically acceptable in terms of applicability, sensitivity and precision.

Method for detecting and distinguishing intrahepatic cholangiocarcinoma

As a result of investigating the optimum conditions of methods for immobilizing proteins that interact with sugar chains onto a substrate, it was revealed that coating the surface of a slide glass with GTMS enables immobilization at a higher S/N ratio than conventionally possible. Moreover, by using a substrate to which a rubber with a number of holes was affixed to form a number of reaction vessels, and further by spotting lectins onto the substrate and washing with PBST, the weak interactions between sugar chains and lectins were successfully detected with improved sensitivity. In addition, by introducing an evanescent excitation-type scanner, it became possible to detect the interactions between lectins and sugar chains without washing away the probe solution.

Methods for analyzing interactions between proteins and sugar chains

Growing community of inventors

Ibaraki, Japan

Atsushi Kuno